Two-drug combination improves survival for operable pancreatic cancer
The results of a large pan-European study by the European Study Group for Pancreatic Cancer (ESPAC) involving 732 patients has shown that the combination of gemcitabine plus capecitabine adjuvant therapy ...Read More »Two-drug combination improves survival for operable pancreatic cancer